X

Vous n'êtes pas connecté

Maroc Maroc - ZACKS.COM - All Stories - 06/Sep 13:22

Novartis to License VYGR's Capsid for Gene Therapy in Neurology

NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.

Articles similaires

Sorry! Image not available at this time

Gene Therapy Reverses a Rare Cause of Vision Loss

drugs.com - 06/Sep 09:09

FRIDAY, Sept. 6, 2024 -- Gene therapy may restore vision to children and adults robbed of their sight by a rare inherited condition called Leber...

A promising new therapeutic target for MASLD identified

news.medical.net - 11/Sep 06:08

Using a novel stem cell platform, a team of the Medical University of South Carolina researchers has identified a pathway that could be targeted by...

Sorry! Image not available at this time

Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

zacks.com - 16:09

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

Sorry! Image not available at this time

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

zacks.com - 13:50

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Sorry! Image not available at this time

Spatial Visualization of Capsid-Dependent Viral Tropism using RNAscope™ ISH Technology, Upcoming Webinar Hosted by Xtalks

bestproductsreview.in  - 06/Sep 12:35

Therefore, the selection of engineered capsids that demonstrate desirable properties is critical to making informed decisions for AAV-based gene...

Sorry! Image not available at this time

Cytel - EMEA: Senior Clinical Programmer

pharmiweb.com - 06/Sep 00:00

Competitive: Cytel - EMEA: Sr. Clinical Programmer   Join Cytel’s enthusiastic and collaborative Biometrics team by contributing to the overall...

Sorry! Image not available at this time

Novartis (NVS) Upgraded to Buy: Here's What You Should Know

zacks.com - 03/Sep 16:00

Novartis (NVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

WHO grants first mpox vaccine approval to ramp up response to disease in Africa and beyond

washingtontimes.com - 13/Sep 10:32

The World Health Organization said Friday it has granted its first authorization for use of a vaccine against mpox in adults, calling it an important...